To the Editor: Cowie et al. (Sept. 17 issue) 1 report on the results of the Treatment of Sleep-Disordered Breathing with Predominant Central Sleep Apnea by Adaptive Servo Ventilation in Patients with ...
The focus of this briefing is the Servo‑n pneumatic life-support system with Neurally Adjusted Ventilatory Assist (NAVA) technology (Getinge Group). It is for babies and children who need ventilator ...
SAN DIEGO, May 13, 2015 /PRNewswire/ -- ResMed (NYSE: RMD) today announced that SERVE-HF, a multinational, multicenter, randomized controlled Phase III trial did not meet its primary endpoint.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback